A Global Perspective on Milestones of Care for Children with Sickle Cell Disease by Sainati, Laura et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
A Global Perspective on Milestones of Care for Children
with Sickle Cell Disease
Laura Sainati, Maria Montanaro and
Raffaella Colombatti
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64656
Provisional chapter
A Global Perspective on Milestones of Care for Children
with Sickle Cell Disease
Laura Sainati, Maria Montanaro and
Raffaella Colombatti
Additional information is available at the end of the chapter
Abstract
Sickle cell disease (SCD) is one of the most common severe and monogenic disorders
worldwide. Acute and chronic complications deeply impact the health of children with
SCD. Milestones of treatment include newborn screening, comprehensive care and
prevention of cerebrovascular complications.
Keywords: sickle cell disease, children, newborn screening, comprehensive care,
stroke
1. Introduction
Sickle  cell  disease  (SCD)  is  one  of  the  most  common  severe  and  monogenic  disorders
worldwide with an average of 300,000 children born annually with sickle syndromes, the
majority in Africa [1, 2]. SCD was initially endemic in areas of malaria disease (Africa, Southern
India,  Mediterranean countries,  Southern Asia),  but  various waves of  migration brought
populations from areas of high prevalence of the HbS gene to the Americas and Europe
(Figure  1).  Moreover,  the  recent  migration  movements  of  the  past  decade  have  further
increased the frequency of SCD in areas where it was generally uncommon. In Europe, SCD
has become the paradigm of immigration hematology [3] and is now the most prevalent
genetic disease in France [4] and the United Kingdom [5]; its frequency is steadily rising in
many other countries of northern, central and southern Europe [6–10] posing a challenge to
health systems. In addition, awareness regarding SCD is increasing in India [11] and in many
African countries [12] where the prevalence of the disease is high. Although in low-resource
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settings a great effort in terms of funding, care and research is still mainly destined to infectious
diseases, the burden SCD poses on mortality and health systems in Africa is finally starting to
be  recognized  [13–16].  Several  African  countries  have  developed  dedicated  services  for
children with SCD [17–20], including newborn screening [21–26]. Patients with SCD in many
centers are being evaluated in a standardized comprehensive manner both in prospective
observational cohorts [17,  19,  27]  and randomized clinical  trials  [28,  29].  Although some
experiences are still conceived as pilot programs and have yet to be scaled up at a national
level, their results are promising and demonstrate increased commitment to tackle SCD at a
global level.
Figure 1. Global distribution of the sickle cell gene. (a) Distribution of the data points. Red dots represent the presence
and blue dots the absence of the HbS gene. The regional subdivisions were informed by Weatherall and Clegg and are
as follows: the Americas (light gray), Africa, including the western part of Saudi Arabia, and Europe (medium gray)
and Asia (dark gray); (b) Raster map of HbS allele frequency (posterior median) generated by a Bayesian model-based
geostatistical framework. The Jenks optimized classification method was used to define the classes; (c) the historical
map of malaria endemicity was digitized from its source using the method outlined in Hay et al. The classes are de-
fined by parasite rates (PR2−10, the proportion of 2- up to 10-year-olds with the parasite in their peripheral blood): ma-
laria-free, PR2−10=0; epidemic, PR2−10=0; hypoendemic, PR2−10<0.10; mesoendemic, PR2−10≥0.10 and <0.50; hyperendemic,
PR2−10≥0.50 and <0.75; holoendemic, PR0−1≥0.75 (this class was measured in 0- up to 1-year-olds). From Piel et al. Global
distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010 Nov 2;
1: 104. Published online 2010 Nov 2. doi: 10.1038/ncomms1104. Copyright © 2010, Nature Publishing Group, a division
of Macmillan Publishers Limited. All Rights Reserved.
SCD can be defined as a globalized disease, and its presence in so ethnically diverse popula-
tions, living in extremely variable environments and in very different socio-cultural societies,
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is a factor that must be taken into consideration when addressing its management. In fact,
although SCD is a monogenic disorder, its phenotype can be highly variable, not only among
individuals, but also among ethnic groups and populations [30, 31].
In this chapter, we will review the management of children with SCD from a global perspective
focusing on the three milestones of care: newborn screening, comprehensive prix-en-charge and
cerebrovascular complications.
2. Neonatal screening programs
Newborn screening programs for SCD allow the early identification of patients, with the
advantage of starting prophylaxis with penicillin at two months of age, significantly reducing
mortality from infections. Moreover, newborn screening allows the early enrollment of
patients in specialized programs of care in reference centers, thereby reducing morbidity and
subsequent mortality from acute and chronic complications and improving quality of life.
The first screening program for SCD has been introduced in the USA since 1975 [32] and in the
UK in 1993 [33].
In 1987, an NIH Consensus Conference stated that every child should be subjected at birth to
screening for HbS to prevent the severe childhood complications of SCD, mainly infections
and splenic sequestration, both potentially fatal [34]. Subsequently, a randomized study
demonstrated the effectiveness of neonatal screening in dramatically reducing infant mortality
from infection, allowing early initiation of prophylaxis with penicillin [35].
International Guidelines on the treatment of SCD recommend universal newborn screening
on a national basis, best if integrated with existing neonatal screening programs and pro-
grams of prix-en-charge in specialized hematology reference centers [5, 36].
The recommendation is that newborn screening for identification of SCD is performed to all
newborns. All patients must be identified promptly and taken in charge by dedicated and
specialized services in order to begin penicillin prophylaxis within two months of age (Strength
of Recommendation A).
Since the late 1980s numerous are the experiences of newborn screening programs, many
organized by national health systems other confined to single-center experiences or supported
by private funding.
2.1. Neonatal screening for SCD: major international experiences
United States—In the United States, the first neonatal screening program for SCD dates back
to the 1970s (State of New York and Columbia), but after the publication of the NIH recom-
mendations, all the states have organized a universal neonatal screening program for the S
gene, associated with neonatal screening for other diseases. The analysis is performed at the
birth from capillary blood taken by pricking the heel and using Guthrie paper. The analysis is
done in most cases by Hygh performance liquid chromatography (HPLC).
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The results of 20 years of the program (1989–2012) show an average incidence of the S gene in
the general population of 1:64 (1.5%) and an average incidence of SCD of 1: 2000 (0.05%) [37].
The program in the United States was effective in significantly reducing the mortality of
children with SCD [38].
Canada—In 1988 a targeted screening pilot program was started at the University of Montreal
on babies with at least one African parent. The test, performed by HPLC, identified a propor-
tion of 10% with trait and 0.8% of the affected. A significant number of non-enrolled patients
was reported by the program, as many as 11 patients born in the reporting period: 5 of 72 of
infants escaped enrollment in a care program, six infants were not identified as affected, and
three false negatives and three inadequate samples were identified, stressing the importance
of an absolute rigor in the organization of a screening program [39].
In 2006 a universal neonatal screening program for SCD, on a national basis, was initiated in
Ontario and subsequently implemented in eight other Canadian provinces, comprising 10
provinces and three territories. The survey is performed on the cord blood or capillary blood
on tissue paper by HPLC, using Iso-Electric-Focusing (IEF) or hemoglobin electrophoresis as
a confirmatory test. A debate is ongoing on whether to inform parents of the carriers subject
[36].
In Brazil, many states organized a neonatal screening program for the identification of patients
with SCD. Since 2001 in the State of Janeiro Rio a universal neonatal screening program is
active, funded by the National Health System, which includes the analysis by HPLC of the
sample from the Guthrie test, performed on the baby after discharge in association with the
first vaccine administration; the program provides for the subsequent taking charge of patients
with SCD at the Reference Center.
The results of the first 10 years of experience (2001–2011) showed a SCD incidence of 1:1335
births and incidence of the trait by about 5% of births [40, 41]. The mortality was 3.7%
significantly lower than the mortality of 25% of a cohort of Brazilian children not included in
a screening program [42] but also significantly lower than that of a population of children
undergoing neonatal screening, but not incorporated in a comprehensive program of follow-
up. In fact, mortality in this population was found to be 5.6% [43]. The importance of integrating
neonatal screening in an effective program of care of the patient at a specialized reference center
has been more recently confirmed by another recent Brazilian study, which indicated in Minias
Gerais State a mortality of 7.5% patients with SCD in the first 14 years of life, even though they
were undergoing newborn screening, because of a non-effective care program [44].
In Europe, although there is strong evidence that hemoglobinopathies are an increasingly
important public health problem [3], as a result of recent migration flows from the Mediter-
ranean countries, Africa and Asia, there is very little data regarding the overall prevalence of
SCD; the health policy of the governments, regarding the management of SCD, is uneven in
the various nations. The European Network for Rare and Congenital Anemias (ENERCA)
estimates that there are around 44,000 people in Europe suffering from hemoglobinopathises,
70% of which are SCD, and strongly recommends that the National Health Systems develop
Sickle Cell Disease - Pain and Common Chronic Complications20
screening programs and specialized reference centers for the care of the patient and their
family [6].
The United Kingdom (UK) was the first European country to organize, in 1993, a universal
neonatal screening program for SCD. The initial pilot program, which began in England, was
updated and since 2010 is extended to the whole of Britain. The program, supported by the
National Health System (NHS), provides universal neonatal screening, performed with
analysis of Guthrie test concurrently with other screenings. Samples are analyzed at 13
reference hematological laboratories by HPLC, each laboratory screening between 25,000 and
100,000 newborns a year. The organization provides for centralized analysis in reference
laboratories, each with a minimum of 25,000 tests per year. The incidence of carriers in the UK
is an average of 15/1000 (1.5%) and 1:1900 (0.05%) with significant variations by region and
ethnicity [45].
A national program of universal newborn screening of Guthrie by HPLC [46] is active in the
Netherlands since 2007. A debate on whether to notify the carrier state to avoid stigmatization
is currently underway [10].
In Belgium, since 1994 in the city of Brussels and in 2004 in the city of Liege, all newborns are
subjected to universal screening for SCD. The analysis of umbilical cord blood is performed
by IEF and HPLC as a possible confirmatory test. The affected frequency is determined to be
1:1559 [47].
In Spain, since 2000 universal neonatal screening programs have been initiated in Extremadura,
Basque Country, Madrid, Valencia and Catalonia with plans of extending it from 2016 to the
whole country. The prevalence of the affected varies from 1:3900 in Catalonia to 1:5900 in the
region of Madrid [8, 48, 49].
In Germany, pilot programs of universal newborn screening were organized since 2011, first in
Berlin, then in Heidelberg and in the Southeast Region of Germany and then in Hamburg. The
tests were offered to all newborns although the original population was not at risk of hemo-
globinopathy. The goal was to provide information about the global prevalence in Germany
of a disease that has high prevalence in immigrant populations, coming mainly from areas at
risk. The test was carried out by PCR for S chain from Guthrie paper in Hamburg, and by HPLC
in the other experiences; the incidence of the affected ranged from 1:2385 to 1:8348 [9].
The results of the pilot studies were considered adequate to justify a universal neonatal
screening program on a national basis, extended to the entire Germany. The activation of the
project is planned for 2016. The carrier status is not communicated for fear of stigma.
Since 1985, France has organized a universal neonatal screening program for SCD in Guade-
loupe: in the following years, many pilots studies were initiated in France; since 2000 a national
screening program targeted at infants at risk of hemoglobinopathy was extended to the entire
country; the selection is based on ethnic belonging. Although the program is not universal, it
appears to be effective in intercepting almost all affected infants, ensuring their ultimate
takeover by the Reference Centres [50].
In Italy, some experiences of neonatal screening for SCD have been reported.
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From 2010 to 2012 in Ferrara, 1992 newborns have been tested and 24 carriers identified (1.2%).
Screening was universal, run on Guthrie by HPLC. The experience was suspended for lack of
funding [51].
In 2013 in Novara a project of newborn screening targeted to babies with a parent coming from
areas at risk of hemoglobinopathy was implemented. A total of 337 of 2447 were tested and 20
carriers identified (6%) [52].
In Modena, since 2011 an antenatal screening program targeted at at-risk women by ethnicity
was developed. The pilot study showed the presence of hemoglobinopathy in 27% of the 330
women tested (coverage of 70% of the program). Successively, the screening of infants of carrier
mothers, run on cordon and analyzed by HPLC, has identified 48 carriers and 9 HbSS [53]. The
universal antenatal screening program, extended to all pregnant women and including infants
at risk of maternal positivity, is currently ongoing and supported with funding from the
Province of Ferrara.
Since 2010, a centralized program of targeted neonatal screening (at least one parent from
outside the region) is active in Friuli Venezia Giulia, financed by the region. The figures, as yet
unpublished, report 6018 infants tested from 2010 to 2015, a percentage of carriers between
1.74 and 4.7% depending on the provinces (F Zanolli, personal communication).
A pilot program of universal newborn screening has been running since May 2, 2016, in Padua
and is currently being activated in Monza.
Africa bears the highest burden of SCD. In the past years, several pilot newborn screening
programs have been implemented in Central Africa [21], Ghana [20, 22], Congo [24], Benin [25],
Angola [26], Nigeria [23, 54, 55] and Uganda [56] and are underway in Tanzania [19]. Some of
the most significant experiences are described in detail below.
The first program started in Ghana in 1995 [22], and after 10 years, a total of 202,244 infants
were screened through public and private clinics in Kumasi, Tikrom and a nearby rural
community. 3745 (1.9%) infants were identified as having possible SCD with IEF: 2047 (1.04%)
SS, 1684 (0.83%) SC.
In Central Africa, between July 2004 and July 2006, 1825 newborn dried blood samples were
collected onto filter papers in four maternity units from Burundi, Rwanda and the East of the
Democratic Republic of Congo. The presence of hemoglobin C and S was tested in the eluted
blood by an enzyme-linked immunosorbent assay (ELISA) test using a monoclonal antibody.
All positive samples were confirmed by DNA analysis. Of the 1825 samples screened, 97
(5.32%) were positive. Of these, 60 (3.28%) samples were heterozygous for Hb S, and four
(0.22%) for Hb C; two (0.11%) newborns were Hb SS homozygotes.
In Uganda [56], punch samples were obtained from dried blood spots routinely collected from
HIV-exposed infants for the national Early Infant Diagnosis program. Between February 2014,
and March 2015, 99,243 dried blood spots were analyzed through IEF, and results were
available for 97,631. The overall number of children with sickle cell trait was 12,979 (13.3%)
and with disease was 716 (0.7%), with extreme variability across regions.
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Two pilot screenings from Nigeria are reported. Obaro et al. (54) screened HPLC children aged
less than 5 years. Overall, 272 (2.76%) new cases from 9963 children who had not been
previously tested were identified. The authors reported also the screening of 163 (1.6%)
children whose parents indicated that their offspring had been previously tested. 31.2% of
parents (51/163) did not know the result of their offspring’s test.
Inusa et al. [55] from January 2010 to December 2011 screened children aged 0–60 months in
29 randomly selected local communities of three adjoining northern Nigerian states in a
community-based study: Abuja, Kaduna and Katsina. For infants of 0–6 months, blood spots
were used, and for infants of 7–60 months, EDTA blood samples were analyzed using HPLC.
Thirty-one selected samples with high Hb A2 (3.5–7.4%) were further analyzed using molec-
ular diagnosis to ascertain the presence of the Beta Thalassemia gene. Of the 10,001 infants and
children screened, 269 (2.69%) had a SCD diagnosis, 90% of which were HbSS (n = 243), 5%
HbSC (n = 13), 3% with high A2>6% (possible S with existence β thalassaemia (n = 9) and 1%
HbSD (n = 2). A total of 74% of infants screened were HbAA (n = 7391). 2341 (23%) were carriers,
96% HbAS (n = 2236), 2% HbAC (n = 51), 1% HbAD (n = 25), and 1% HbABeta-thal (n = 22).
HbSβo was confirmed by molecular analysis from the 31 selected samples.
3. Management of sickle cell disease in childhood
SCD is a chronic and complex multisystem disorder requiring comprehensive care that
includes screening, prevention, health education, management of acute and chronic compli-
cations [5, 57]. Poor service organization and episodic health care cause higher rates of acute
events and chronic complications, with subsequent increased burden on hospital structures
and higher costs for health systems [58].
Neonatal screening program for SCD is not successful without a comprehensive care program
at a specialized reference center for the treatment of the disease.
The organization of the Comprehensive Sickle Cell Centers proved crucial integration of
screening programs, providing health education, preventive treatment (prophylaxis of
infections, up-to-date vaccinations, stroke prevention), appropriate diagnostic therapeutic
pathways for the treatment of acute and chronic complications, planning of blood transfusion
and administration of HU, accompanying the transition to adult care for adolescents and
young adults through structured transition programs. The care delivered by a specialized and
multidisciplinary team in referral centers is effective in reducing mortality and improving the
quality of life [38, 59]. Where these facilities were lacking, the effectiveness of neonatal
screening program was reduced [60].
A recommended examinations schedule for yearly follow-up of children with SCD is shown
in Table 1 [61], while the services that a reference center should offer are displayed in Table 2
[5].
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Table 1. Recommended examinations to be performed annually in children with SCD [60].
◦ Pediatrician or hematologist with hemoglobinopathies skills
◦ Dedicated outpatient clinic
◦ Network with the territory and the peripheral hospitals
◦ Diagnostic laboratory
◦ Newborn screening program
◦ Transcranial Doppler service
◦ Pediatric intensive care
◦ Transfusion service
◦ Pediatric specialist services (cardiology, urology, nephrology, pulmonology, endocrinology, orthopedics, surgery,
anesthesia, ophthalmology, dentistry)
◦ Psychology service with availability of psychometric assessments
◦ Radiology and neuroradiology
◦ Bone marrow transplant unit
◦ Adult-specialist team for the transition program
Table 2. Characteristics of a specialized reference center [5] and services that it should be able to offer directly or in
agreement with nearby centers.
A comprehensive approach to the care of children with SCD should include the following
goals: to improve quality of life, by preventing and treating infections, adequate pain man-
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agement and anemia control; to prevent organ damage, mainly stroke, renal and lung; to
prevent SCD related mortality [61].
3.1. Management of sickle cell disease in childhood: open issues at a global level
In spite of the strong evidence to perform newborn screening and comprehensive care, these
services are far from optimally delivered to patients with SCD not only in Europe and the USA,
but mainly in areas of Africa and India where the majority of the children with SCD live. Many
pilot programs were initiated in the last decade in many countries of Latin America, Middle
East, Asia, and Africa; some were integrated with other screening programs. These data are
encouraging but such programs need to be further enhanced.
Increased North-South, South-South and East-West collaboration could be an important way
to increase service delivery to all affected children.
4. Cerebrovascular complications of sickle cell disease: stroke and silent
infarcts
In the most severe forms of SCD, the homozygous SS and the double etherozygous Sβ°, the
brain is frequently affected (Figure 2). Overt ischemic stroke occurs in 11% of untreated
children as a result of stenosis or occlusion in the large arteries of the Circle of Willis [62, 63].
Cerebral silent infarcts (CSI), affecting 40% of children by the age of 14, are caused by small
vessel disease [64, 65] although recent evidence suggests that also a combination of chronic
hypoperfusion or hypoxic events, favored by an underlying artheropathy of the large vessels,
can lead to CSI [66]. In the past 15 years, improvements have been made in the management
of stroke and CSI [66, 67]. In fact, algorithms for screening, prevention and management of
stroke and CSI based on neuroimaging techniques such as transcranial Doppler (TCD) and
Figure 2. Stenosis on magnetic resonance angiography (left) and silent infarcts on magnetic resonance imaging (right).
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magnetic resonance imaging/angiography (MRI/MRA) are routinely used in clinical practice
[67–70].
TCD screening is recommended starting at age 2 years in children with HbSS and HbSβ°, and
those identified at risk of stroke are offered chronic transfusion as stroke prevention [67]. Stroke
can be virtually eliminated or dramatically reduced if a proper TCD screening program
followed by chronic transfusion for at risk patients is established [59, 68]. Recently, a random-
ized study demonstrated that after one year of chronic transfusion, hydroxycarbamide (HU)
can be safely offered to children with normal neuroimaging under strict surveillance [71].
While TCD allows identifying patients at risk of stroke and initiate appropriate treatment, it
is not useful to screen for the other cerebrovascular complications of SCD such us CSI.
Moreover, its usefulness in identifying risk of stroke in other genotypes of SCD such as HbSC
and HbSβ+, in which stroke is less common, has yet to be evaluated.
Screening with MRI/MRA, although unable to indentify children at risk of developing CSI, is
strongly recommended in many centers starting at age 5 years, when sedation is no longer
necessary [66, 68, 72], to ensure diagnosis at young age and promptly start therapeutic or
educational measures. In case of abnormal TCD, developmental delay or cognitive impairment
or any other clinical reason, MRI is indicated even before 5 years of age. Both chronic trans-
fusions and HU have been shown to stabilize CSI [66, 67, 73], but at present there is no general
agreement on prevention strategies.
4.1. Stroke and silent infarcts: open issues at a global level
In spite of extensive research performed in the United States and Europe on the management
of stroke and CSI in children with SCD in the past decades, the delivery of routine TCD
screening to children with SCD has been quite low. Primary stroke prevention through TCD
is recommended in all national and international guidelines, but less than 50% of children in
the USA [74] and the United Kingdom benefit from this technique [75]. Data regarding the
coverage of TCD screening are not available for other countries of Europe, South America or
the Middle East at a national level, but only for single-center experiences [59, 66, 69, 72, 76],
and this is a gap that should be filled.
TCD data are not yet available from many areas of the world like India, Northern and Sub-
Saharian Africa. Nevertheless, personnel training on the correct protocol of TCD screening for
SCD has been performed in Africa, and promising pilot studies are being conducted in
Nigeria [77–79]. These studies demonstrate the feasibility of primary and secondary preven-
tion programs in low-resource settings with huge numbers of patients. They also allow us to
explore the efficacy of alternative protocols compared to those in use in the USA and Europe
and to demonstrate the benefit of HU in reducing TCD velocities [80].
A challenge that a global approach to SCD can address is the reported variability of stroke and
cerebrovascular complications in populations of different ethnic backgrounds. Stroke and CSI
seem to occur with different frequencies across populations, although data are still poor and
warrant further investigation [81–85]. Moreover, biological factors such as G6PD deficiency
and alfa thalassemia co-inheritance as well as coagulation activation and single nucleotide
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polymorphisms (SNPSs) do not seem to have the same role on the genesis of cerebrovascular
complications in different populations [86–90].
In conclusion, more TCD and MRI/MRA data from SCD populations across the world could
aid in designing wide population studies to explore genetic and biological modifying factors
of cerebrovascular disease as currently performed in other pathologic conditions [91]. Coor-
dinating cerebrovascular studies across countries and continents can be challenging [79, 92–
95] but is now warranted to improve patients access to recommended screening tools and to
better target treatment interventions according to biological disease-modifying factors, which
may vary across ethnicities.
5. Future directions
The main objective would be to increase the access to the milestones of care:
- Expand universal newborn screening to all Countries with sufficient prevalence of disease
- Expand access to vaccinations, antibiotic prophylaxis and transcranial Doppler for stroke
prevention, by increasing the number of skilled personnel and service availability
- Increase the use of disease-modifying treatments for the pediatric age, such as hydroxiurea,
in formulations that are suitable for children (low dose tablets or syrups) in all countries
Strengthening collaboration at a global level and developing North-South, South-South and
East-West partnerships could aid in reaching the above mentioned aims.
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